Argos Therapeutics Inc. (NASDAQ:ARGS) major shareholder International S. Pharmstandard purchased 31,704 shares of the business’s stock in a transaction on Friday, October 7th. The shares were acquired at an average price of $4.73 per share, for a total transaction of $149,959.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of Argos Therapeutics Inc. (NASDAQ:ARGS) opened at 4.61 on Monday. The company’s 50 day moving average is $4.89 and its 200-day moving average is $5.89. The stock’s market capitalization is $189.91 million. Argos Therapeutics Inc. has a 1-year low of $1.61 and a 1-year high of $13.97.
Argos Therapeutics (NASDAQ:ARGS) last issued its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by $0.05. Equities analysts anticipate that Argos Therapeutics Inc. will post ($1.56) earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the company. Schwab Charles Investment Management Inc. acquired a new stake in shares of Argos Therapeutics during the second quarter worth about $137,000. California State Teachers Retirement System acquired a new stake in shares of Argos Therapeutics during the second quarter worth about $137,000. KCG Holdings Inc. acquired a new stake in shares of Argos Therapeutics during the second quarter worth about $163,000. BlackRock Investment Management LLC raised its stake in shares of Argos Therapeutics by 2,162.3% in the second quarter. BlackRock Investment Management LLC now owns 39,567 shares of the biopharmaceutical company’s stock worth $243,000 after buying an additional 37,818 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Argos Therapeutics by 7.9% in the first quarter. Geode Capital Management LLC now owns 48,851 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 3,559 shares during the last quarter. 11.03% of the stock is currently owned by hedge funds and other institutional investors.
A number of brokerages have issued reports on ARGS. Zacks Investment Research lowered shares of Argos Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 13th. FBR & Co cut their price target on shares of Argos Therapeutics from $14.00 to $13.00 and set an “outperform” rating on the stock in a research note on Thursday, August 11th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and set a $11.00 price target on shares of Argos Therapeutics in a research note on Monday, June 20th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Argos Therapeutics has a consensus rating of “Buy” and an average target price of $11.50.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.